In a report released today, Florent Cespedes from Bernstein maintained a Hold rating on Novo Nordisk (0QIU – Research Report), with a price ...

By contrast, Novo Nordisk is both the developer and seller of Wegovy, while Viking Therapeutics's VK2735 has posted impressive results in testing and is now in the later stages of development. Wegovy ...

Novo Nordisk faces challenges but its pipeline remains strong. Find out why NVO stock could deliver high double-digit returns ...

Goldman Sachs analyst James Quigley maintained a Buy rating on Novo Nordisk (0QIU – Research Report) today and set a price target of DKK890.00.

Taking into account the Volume and Open Interest on these contracts, it appears that whales have been targeting a price range from $70.0 to $150.0 for Novo Nordisk over the last 3 months.

Chinese tech stock trading in Hong Kong was poised to enter a technical bull market after DeepSeek’s artificial intelligence ...

Failed to fetch dynamically imported module: https://nz.finance.yahoo.com/assets/_app/immutable/nodes/19.BMtwm98i.js ...

Chinese tech stock trading in Hong Kong was poised to enter a technical bull market after DeepSeek’s artificial intelligence ...

Contracts on the S&P 500 ( ES=F) and the tech-heavy Nasdaq 100 ( NQ=F) were down 0.2%. Dow Jones Industrial Average futures ( ...

European shares were edging lower on Friday as investors waited for monthly U.S. labor market data. The continent's flagship ...

In its outlook for 2025, Novo Nordisk has predicted 'continued periodic supply constraints and related drug shortage ...